Joy-Rides Tablets - Product Information
|Manufacture:||Forest Laboratories, Inc.|
|Ingredients:||hyoscine hydrobromide, mannitol, erythrosine (E 127), povidone, raspberry flavour, microcrystalline cellulose, magnesium stearate|
Name of the Medicinal Product
Qualitative and Quantitative Composition
Hyoscine hydrobromide 0.15 mg
For a full list of excipients, see section List of Excipients.
A raspberry flavoured chewed tablet for oral administration.
Anti-muscarinic. For the prevention of motion sickness.
Posology and Method of Administration
|Route of administration:||Oral.|
|Adults over 13 years:||2 tablets 20 minutes before start of the journey. Maximum 4 tablets in 24 hours.|
|Children:||20 minutes before journey. 7 - 12 years: 1 -2 tablets. 4 - 7 years: 1 tablet. Maximum 2 tablets in 24 hours. 3 – 4 years: half a tablet. Maximum 1 tablet in 24 hours.
Not recommended under 3 years except on medical advice.
Ideally taken 20 minutes before the start of the journey. However, still effective if taken at onset of nausea or after the journey has begun.
Special Warnings and Precautions for Use
Do not exceed the stated dose. Avoid alcoholic drink.
If you are epileptic, you might suffer from increased seizure frequency.
Interaction with Other Medicinal Products and Other Forms of Interaction
The actions of hyoscine hydrobromide may be potentiated by concurrent phenothiazines, tricyclic antidepressants or alcohol. Aluminium hydroxide preparations may reduce absorption of hyoscine hydrobromide. The actions of tricyclic antidepressants may be potentiated by concurrent hyoscine hydrobromide.
Pregnancy and Lactation
Safety in pregnancy has not been established, but the drug has been used widely for many years without apparent ill effect. However, the normal precautions of avoiding unnecessary medication especially in the first trimester of pregnancy should be observed.
Hyoscine hydrobromide can cross the placenta and appears in trace quantities in breast milk.
Effects on Ability to Drive and Use Machines
May cause drowsiness, if affected do not drive or operate machinery.
Some patients may experience cholinergic signs and symptoms such as dry mouth, dizziness, blurred vision, dilatation of the pupils with loss of accommodation, photophobia, closed angle glaucoma (very rare), urinary disturbances (urinary emergency and retention), reduced bronchial secretions, transient bradycardia (followed by tachycardia, palpitation and arrhythmias), flushing and dryness of the skin, constipation, nausea and vomiting.
Other signs and symptoms may include hallucination, high temperature (due to decreased sweating) and confusion. These may occur in all patient groups although certain populations (children and the elderly) are more susceptible to anticholinergic toxicity.
Reporting of Suspected Adverse Reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
The main symptoms are sleepiness, dry mouth, rapid heart rate, palpitation, dilated pupils. Other signs and symptoms may include hallucination, high temperature and confusion. These may occur in all patient groups although certain populations (children and the elderly) are more susceptible of anticholinergic toxicity. Take measures to limit intestinal absorption immediately. Parasympathetic agents such as physotigmine should be used as necessary. Do not use phenothiazines.
The Atropine like actions of hyoscine hydrobromide are well known. The site of action in preventing motion sickness is thought to be either on the cortex or more peripherally on the vestibular apparatus.
Hyoscine is rapidly absorbed from the gastro-intestinal tract. About 1 % of an oral dose is eliminated as such in the urine. Traces are found in various secretions, including milk.
Preclinical Safety Data
List of Excipients
Erythrosine (E.127) Lake
Raspberry Flavour Trusil J7551
Special Precautions for Storage
Store below 25°C in a dry place.
Nature and Contents of Container
Tablets are inpidually sealed in strips of 12, or as 2 strips of 6, between 2 layers of 0.25 mm soft aluminium foil/0.25 mm polyethylene. Strips are packed in decorated, folding boxboard cartons.
Special Precautions for Disposal and Other Handling
Marketing Authorisation Holder
Forest Laboratories UK Limited,
Marketing Authorisation Number(s)
Date of First Authorisation/Renewal of the Authorisation
First granted 22 July 1973.
Last renewed 12 April 1996.
Date of Revision of the Text
Company Contact Details
Forest Laboratories UK Limited (a subsidiary of Actavis PLC)
Whiddon Valley, Barnstaple, Devon, EX32 8NS, UK
+44 (0)1271 346106
Medical Information e-mail
+44 (0)1271 311 200
Medical Information Direct Line
+44(0)1271 385 257